Top 10 Drug Delivery Technologies (2010 - 2015)

  • February 2011
  • -
  • MarketsandMarkets
  • -
  • 350 pages

STUDY GOALS AND OBJECTIVES

-To define and measure drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics and others.
-To identify major drivers and restraints of the market
-To evaluate comprehensively all drug delivery technologies and benchmark them against various parameters to identify top ten technologies.
-To identify and analyze comprehensively market structure with respect to the factors influencing market growth and industry specific challenges.
-To analyze trends and forecasts of drug delivery market and its segments
-To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.
-To analyze opportunities in the market for stakeholders
-To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market
-To understand regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.
-To analyze and forecast revenues of market segments with respect to geographies (North America, Europe, Asia and Rest of the World
-To provide comprehensive analysis of top players in the drug delivery technology market.
-To effectively scope out and justify evaluation and provide sufficient basis of ranking top ten drug delivery technologies.

REASONS FOR DOING THE STUDY

More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body (pharmacokinetics) therefore signifying the importance of drug delivery systems. Rapid enhancements in drug discovery technologies have lead to developments in proteomics and genomics and had a greater impact on drug delivery technology market. The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.

SCOPE AND FORMAT

Top 10 Drug Delivery Technologies Market research report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are:
-Oral drug delivery technologies
-Injectable drug delivery technologies
-Pulmonary drug delivery technologies
--Transdermal drug delivery technologies
Other drug delivery technologies
The report also focuses on the emerging drug delivery technologies and mechanisms.

INTENDED AUDIENCES
-Drug delivery technology – manufacturers, suppliers and dealers
-Pharmaceutical and biotech companies
-Healthcare providers
-Potential investors in the drug delivery technology market

INFORMATION SOURCES
Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides 40 companies. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.

Table Of Contents

TABLE OF CONTENTS


EXECUTIVE SUMMARY
OBJECTIVE
MARKET SCENARIO
EMERGING TECHNOLOGIES

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY

2 SUMMARY

3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE
3.3 STAKEHOLDERS
3.4 CHALLENGES
3.4.1 GOVERNMENT REGULATIONS
3.4.2 PRICING PRESSURE, REIMBURSEMENTS, and THIRD-PARTY DEPENDENCE
3.4.3 PATENT LITIGATIONS
3.4.4 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES
3.5 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS
3.6 PATENT ANALYSIS

4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 PATENT EXPIRATION OF DRUGS
4.2.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS and BIOPHARMACEUTICALS
4.2.3 REDUCE ATTRITION RATES and FASTER DRUG DISCOVERY/DEVELOPMENT PROCESSES
4.2.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY
4.2.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES
4.3 RESTRAINTS
4.3.1 DRUG FAILURES RAISE CONCERNS ON ROI
4.3.2 U.S. HEALTHCARE REFORMS
4.4 OPPORTUNITIES
4.4.1 HOME-CARE DRUG DELIVERY DEVICES and SELF-ADMINISTRATION
4.4.2 NICHE THERAPEUTIC AREAS
4.4.3 WELLNESS PRODUCTS

5 CONTROLLED RELEASE TECHNOLOGY
5.1 INTRODUCTION
5.1.1 KEY MARKET PLAYERS
5.2 DRIVERS
5.2.1 CONTROLLED RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS
5.2.2 ONCE-A-DAY FORMULATIONS
5.2.3 COST EFFECTIVE
5.3 RESTRAINTS
5.3.1 LIMITED NUMBER OF MATERIALS
5.3.2 TECHNICAL BARRIERS
5.4 OPPORTUNITIES
5.4.1 PARTICULATE and CHRONOPHARMACOKINETIC SYSTEMS
5.4.2 MUCOADHESIVE DRUG DELIVERY
5.5 BIODEGRADABLE POLYMERS
5.6 HYDROGEL
5.7 MULTIPARTICULATE BEAD SYSTEMS
5.8 ION EXCHANGE RESINS
5.9 OSMOTIC PRESSURE CONTROLLED SYSTEMS
5.10 DISSOLUTION/DIFFUSION SYSTEMS
5.10.1 MATRIX SYSTEMS
5.10.2 RESERVOIR SYSTEMS
5.11 OTHERS
5.12 REGULATORY ENVIRONMENT
5.13 CONTROLLED RELEASE VS IMMEDIATE RELEASE FORMULATIONS
5.14 INNOVATIONS IN CONTROLLED RELEASE TECHNOLOGIES
5.15 BURNING ISSUES
5.16 WINNING IMPERATIVES
5.17 COMPETITIVE DEVELOPMENTS

6 TARGETED DELIVERY
6.1 INTRODUCTION
6.1.1 KEY MARKET PLAYERS
6.2 DRIVERS and RESTRAINTS
6.2.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS
6.2.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR
6.2.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS
6.3 OPPORTUNITY
6.3.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS
6.4 TARGETING LIGANDS
6.4.1.1 Antibody fragment drug conjugate delivery
6.4.1.2 Antibody directed enzyme prodrug targeted delivery
6.4.1.3 Peptide-targeted delivery
6.4.1.4 Small molecule conjugate delivery
6.4.1.5 Others
6.5 NON-BIOLOGICAL TARGETING PLATFORMS
6.6 CURRENTLY MARKETED TARGETED THERAPIES
6.7 IMPACT OF TARGETED DRUG DELIVERY IN CANCER and OTHER CHRONIC CONDITIONS
6.8 INNOVATIONS
6.9 INDUSTRY INSIGHTS
6.10 WINNING IMPERATIVES

7 ENCAPSULATION TECHNOLOGIES
7.1 INTRODUCTION
7.1.1 KEY MARKET PLAYERS
7.2 DRIVERS and RESTRAINTS
7.2.1 ENHANCED BIOAVAILABILITY
7.2.2 EXTENSIVE USAGE IN TASTE MASKING and FASTER DISSOLVING PILLS
7.2.3 ECONOMICALLY FEASIBLE
7.2.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES
7.3 OPPORTUNITY
7.3.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS
7.4 TASTE MASKING
7.5 FAST DISSOLVING PILLS
7.6 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
7.7 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY
7.8 INDUSTRY INSIGHTS
7.9 WINNING IMPERATIVES
7.10 COMPETITIVE DEVELOPMENTS

8 TOPICAL FORMULATIONS
8.1 INTRODUCTION
8.1.1 KEY MARKET PLAYERS
8.2 DRIVERS and RESTRAINTS
8.2.1 BURN and WOUND TREATMENT
8.2.2 BYPASSING FIRST PASS EFFECT
8.2.3 CONVENIENCE FACTOR
8.2.4 USAGE IN LIMITED THERAPEUTIC AREAS
8.3 OPPORTUNITY
8.3.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS
8.4 GEL TECHNOLOGY
8.5 MICROEMULSIONS
8.6 BIPHASIC SYSTEM
8.7 OTHERS
8.8 INDUSTRY INSIGHTS
8.9 WINNING IMPERATIVES
8.10 COMPETITIVE DEVELOPMENTS

9 INHALER TECHNOLOGY
9.1 INTRODUCTION
9.1.1 KEY MARKET PLAYERS
9.2 DRIVERS and RESTRAINTS
9.2.1 INCREASE IN ASTHMA and COPD PATIENTS
9.2.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN
9.2.3 EASE OF USE, SELF-ADMINISTRATION, and PAINLESS DRUG DELIVERY
9.2.4 FAILURE OF EXUBERA
9.3 OPPORTUNITY
9.3.1 APPLICATION IN NON-RESPIRATORY CONDITIONS
9.4 DRY POWDER INHALERS
9.5 METERED DOSE INHALERS
9.6 NEBULIZERS
9.7 EVOLUTION OF INHALER DEVICES
9.8 REGULATORY ENVIRONMENT
9.9 TECHNOLOGY INNOVATIONS
9.10 INDUSTRY INSIGHTS
9.11 WINNING IMPERATIVES
9.12 COMPETITIVE DEVELOPMENTS

10 INJECTABLE DRUG DELIVERY
10.1 INJECTION DEVICES
10.1.1 KEY MARKET DYNAMICS
10.1.1.1 Drivers
10.1.1.1.1 Growth of self-administration therapies
10.1.1.1.2 Needle-stick legislation
10.1.1.1.3 Increasing acceptance by physicians and patients
10.1.1.1.4 Reducing cost of treatment
10.1.1.2 Restraints
10.1.1.2.1 Need of new drug formulation
10.1.1.3 Opportunities
10.1.1.3.1 Product differentiation through added functional features
10.1.1.3.2 Expansion to new areas
10.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE
10.3 KEY DEVELOPMENTS
10.3.1 DEVELOPMENT OF MICRONEEDLES
10.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS
10.4 CONVENTIONAL INJECTABLES
10.5 PREFILLED SYRINGES (PFS)
10.5.1 KEY MARKET DYNAMICS
10.5.1.1 Drivers
10.5.1.1.1 Growing market for self-injection devices
10.5.1.1.2 Wastage control and cost reduction through less overfill
10.5.1.1.3 Ease of manufacture and convenient usability
10.5.1.2 Restraints
10.5.1.2.1 Threat from needle-free devices
10.5.1.2.2 Protecting product quality
10.5.2 GLASS PFS
10.5.3 PLASTIC PFS
10.6 SELF INJECTION DEVICES
10.6.1 AUTO INJECTORS
10.6.1.1 Reusable auto-injectors
10.6.1.2 Disposable auto-injectors
10.6.2 PEN INJECTORS
10.6.2.1 Reusable pen injectors
10.6.2.2 Disposable pen injectors
10.6.3 NEEDLE-FREE INJECTORS (NFI)
10.6.3.1 Reusable NFIs
10.6.3.2 Disposable NFIs
10.7 OTHERS

11 TRANSDERMAL PATCH
11.1 INTRODUCTION
11.1.1 KEY MARKET PLAYERS
11.2 DRIVERS
11.2.1 REDUCED SIDE EFFECTS and BETTER EFFICACY
11.2.2 CONVENIENT and LESS PAINFUL
11.3 RESTRAINTS
11.3.1 RECALL OF DURAGESIC and NEGATIVE PUBLICITY OF ORTHO EVRA PATCH
11.3.2 LOW SKIN PERMEABILITY OF DRUGS
11.4 OPPORTUNITIES
11.4.1 NEW PRODUCTS
11.4.1.1 Contraceptive patch
11.4.1.2 Pain management patch
11.4.1.3 Estrogen/hormone replacement patch
11.5 INDUSTRY INSIGHTS
11.6 WINNING IMPERATIVES
11.7 COMPETITIVE DEVELOPMENTS

12 IMPLANTABLE DRUG DELIVERY
12.1 INTRODUCTION
12.2 DRIVERS and RESTRAINTS
12.2.1 SELECTIVE DRUG DELIVERY and LOW AMOUNT OF ACTIVE DRUG INGREDIENT
12.2.2 DOSING ADMINISTRATION NOT REQUIRED
12.2.3 INCONVENIENCE
12.3 OPPORTUNITY
12.3.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS
12.4 CORONARY (DRUG ELUTING) STENTS
12.5 IMPLANTABLE INFUSION PUMPS
12.6 OCULAR IMPLANTS and OTHERS
12.7 INDUSTRY INSIGHTS
12.8 WINNING IMPERATIVES

13 LIPOSOMAL DRUG DELIVERY
13.1 INTRODUCTION
13.2 DRIVERS and RESTRAINTS
13.2.1 ENHANCED USAGE IN CANCER
13.2.2 EASY MANUFACTURING PROCEDURE and COST EFFECTIVENESS
13.2.3 SIDE EFFECTS
13.3 OPPORTUNITY
13.3.1 NANOSCALE LIPOSOME DRUG DELIVERY
13.4 INDUSTRY INSIGHTS
13.5 WINNING IMPERATIVES
13.6 COMPETITIVE DEVELOPMENTS

14 PEGYLATION TECHNOLOGIES
14.1 INTRODUCTION
14.2 DRIVERS and RESTRAINTS
14.2.1 BIOLOGICAL DRUGS
14.2.2 ENHANCED PHARMACOKINETIC PROPERTIES and REDUCED DOSAGE
14.2.3 EXPENSIVE MANUFACTURING PROCEDURE
14.3 OPPORTUNITY
14.3.1 TECHNOLOGICAL ADVANCES
14.4 INDUSTRY INSIGHTS
14.5 WINNING IMPERATIVES

15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 ANALYSIS OF TOP PLAYERS
15.2.1 STRATEGY
15.2.2 INJECTABLE DRUG DELIVERY DEVICES MARKET SHARE
15.2.2.1 Top injectable drug delivery device companies and revenues, by segment
15.3 WINNING IMPERATIVES
15.3.1 ALLIANCES
15.3.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY
15.3.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS
15.4 STRATEGIC RECOMMENDATIONS

16 GEOGRAPHIC ANALYSIS
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.3 EUROPE
16.4 ASIA
16.5 REST OF THE WORLD (ROW)
16.6 DECISION SUPPORT DATABASE

17 COMPANY PROFILES
17.1 3M COMPANY
17.1.1 OVERVIEW
17.1.2 FINANCIALS
17.1.3 PRODUCTS and SERVICES
17.1.4 STRATEGY
17.1.5 DEVELOPMENTS
17.2 ALKERMES, INC
17.2.1 OVERVIEW
17.2.2 FINANCIALS
17.2.3 PRODUCTS and SERVICES
17.2.4 STRATEGY
17.2.5 DEVELOPMENTS
17.3 ALTEA THERAPEUTICS INC.
17.3.1 OVERVIEW
17.3.2 PRODUCTS and SERVICES
17.3.3 STRATEGY
17.3.4 DEVELOPMENTS
17.4 ANTARES PHARMA INC.
17.4.1 OVERVIEW
17.4.2 FINANCIALS
17.4.3 PRODUCTS and SERVICES
17.4.4 STRATEGY
17.4.5 DEVELOPMENTS
17.5 A.P. PHARMA, INC.
17.5.1 OVERVIEW
17.5.2 FINANCIALS
17.5.3 PRODUCTS and SERVICES
17.5.4 STRATEGY
17.5.5 DEVELOPMENTS
17.6 APPLIED PHARMA
17.6.1 OVERVIEW
17.6.2 PRODUCTS and SERVICES
17.6.3 STRATEGY
17.6.4 DEVELOPMENTS
17.7 ARADIGM CORPORATION
17.7.1 OVERVIEW
17.7.2 FINANCIALS
17.7.3 PRODUCTS and SERVICES
17.7.4 STRATEGY
17.7.5 DEVELOPMENTS
17.8 BAXTER BIOPHARMA
17.8.1 OVERVIEW
17.8.2 PRODUCTS and SERVICES
17.8.3 FINANCIALS
17.8.4 STRATEGY
17.8.5 DEVELOP0MENTS
17.9 BECTON, DICKINSON AND COMPANY
17.9.1 OVERVIEW
17.9.2 PRODUCT and SERVICES
17.9.3 FINANCIALS
17.9.4 STRATEGY
17.9.5 DEVELOPMENTS
17.10 BIOJECT INC.
17.10.1 OVERVIEW
17.10.2 FINANCIALS
17.10.3 PRODUCTS and SERVICES
17.10.4 STRATEGY
17.10.5 DEVELOPMENTS
17.11 BIOVAIL CORPORATION (VALEANT PHARMACEUTICALS INTERNATIONAL INC.)
17.11.1 OVERVIEW
17.11.2 PRODUCTS and SERVICES
17.11.3 FINANCIALS
17.11.4 STRATEGY
17.11.5 DEVELOPMENTS
17.12 CIMA LABS INC.
17.12.1 OVERVIEW
17.12.2 PRODUCTS and SERVICES
17.12.3 STRATEGY
17.12.4 DEVELOPMENTS
17.13 ELAN CORPORATION PLC.
17.13.1 OVERVIEW
17.13.2 FINANCIALS
17.13.3 PRODUCTS and SERVICES
17.13.4 STRATEGY
17.13.5 DEVELOPMENTS
17.14 ENDO PHARMACEUTICALS
17.14.1 OVERVIEW
17.14.2 FINANCIALS
17.14.3 PRODUCTS and SERVICES
17.14.4 STRATEGY
17.14.5 DEVELOPMENTS
17.15 EURAND PHARMACEUTICALS
17.15.1 OVERVIEW
17.15.2 FINANCIALS
17.15.3 PRODUCTS and SERVICES
17.15.4 STRATEGY
17.15.5 DEVELOPMENTS
17.16 FLAMEL TECHNOLOGIES, INC
17.16.1 OVERVIEW
17.16.2 FINANCIALS
17.16.3 PRODUCTS and SERVICES
17.16.4 STRATEGY
17.16.5 DEVELOPMENTS
17.17 JOHNSON and JOHNSON LTD.
17.17.1 OVERVIEW
17.17.2 FINANCIALS
17.17.3 PRODUCTS and SERVICES
17.17.4 STRATEGY
17.17.5 DEVELOPMENTS
17.18 KV PHARMACEUTICAL
17.18.1 OVERVIEW
17.18.2 FINANCIALS
17.18.3 PRODUCTS and SERVICES
17.18.4 STRATEGY
17.18.5 DEVELOPMENTS
17.19 LABOPHARM INC.
17.19.1 OVERVIEW
17.19.2 FINANCIALS
17.19.3 PRODUCTS and SERVICES
17.19.4 STRATEGY
17.19.5 DEVELOPMENTS
17.20 NANOPASS TECHNOLOGIES LTD.
17.20.1 OVERVIEW
17.20.2 PRODUCTS and SERVICES
17.20.3 STRATEGY
17.20.4 DEVELOPMENTS
17.21 NEKTAR THERAPEUTICS
17.21.1 OVERVIEW
17.21.2 FINANCIALS
17.21.3 PRODUCTS and SERVICES
17.21.4 STRATEGY
17.21.5 DEVELOPMENTS
17.22 QLT INC.
17.22.1 OVERVIEW
17.22.2 FINANCIALS
17.22.3 PRODUCTS and SERVICES
17.22.4 STRATEGY
17.22.5 DEVELOPMENTS
17.23 SKYEPHARMA PLC.
17.23.1 OVERVIEW
17.23.2 FINANCIALS
17.23.3 PRODUCTS and SERVICES
17.23.4 STRATEGY
17.23.5 DEVELOPMENTS
17.24 SURMODICS, INC.
17.24.1 OVERVIEW
17.24.2 PRODUCTS and SERVICES
17.24.3 FINANCIALS
17.24.4 STRATEGY
17.24.5 DEVELOPMENTS
17.25 VECTURA GROUP PLC
17.25.1 OVERVIEW
17.25.2 FINANCIALS
17.25.3 PRODUCTS and SERVICES
17.25.4 STRATEGY
17.25.5 DEVELOPMENTS
17.26 YPSOMED HOLDING AG
17.26.1 OVERVIEW
17.26.2 FINANCIALS
17.26.3 PRODUCTS and SERVICES
17.26.4 STRATEGY
17.26.5 DEVELOPMENTS
17.27 ZOGENIX, INC.
17.27.1 OVERVIEW
17.27.2 PRODUCTS and SERVICES
17.27.3 STRATEGY
17.27.4 DEVELOP0MENTS

APPENDIX
U.S. PATENTS
EUROPE PATENTS
JAPAN PATENTS


LIST OF TABLES

TABLE 1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS, 2008 - 2015 ($MILLION)
TABLE 2 DRUGS SET FOR PATENT EXPIRATION, 2010 - 2012
TABLE 3 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 4 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 5 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 7 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 8 GLOBAL HYDROGEL MARKET, BY GEOGRAPHY 2008 - 2015 ($MILLION)
TABLE 9 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 10 GLOBAL ION EXCHANGE RESINS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 11 GLOBAL OSMOTIC PRESSURE CONTROLLED SYSTEMS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 12 GLOBAL DISSOLUTION/DIFFUSION SYSTEMS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 13 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 14 GLOBAL RESERVOIR SYSTEMS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 15 GLOBAL OTHER CONTROLLED RELEASE SYSTEMS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 16 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 17 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 18 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 19 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 20 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 21 GLOBAL ANTIBODY FRAGMENT CONJUGATE DELIVERY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 22 GLOBAL ANTIBODY ENZYME DIRECTED PRODRUG DELIVERY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 23 GLOBAL PEPTIDE TARGETED DRUG DELIVERY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 24 GLOBAL SMALL MOLECULE CONJUGATE DELIVERY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 25 GLOBAL OTHER TARGETING LIGANDS BASED DELIVERY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 26 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 27 GLOBAL ENCAPSULATION TECHNOLOGY MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 28 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 29 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 30 GLOBAL ENCAPSULATION MARKET IN TASTE MASKING, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 31 GLOBAL ENCAPSULATION MARKET IN FAST DISSOLVING, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 32 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 33 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY, 2008 - 2015
TABLE 34 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 35 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 36 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 37 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 38 GLOBAL OTHER TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 39 GLOBAL INHALER TECHNOLOGY MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 40 GLOBAL INHALER TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 41 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 42 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 43 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 44 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 45 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 46 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
TABLE 47 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 48 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 49 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 50 GLOBAL PREFILLED SYRINGES MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 51 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 52 GLOBAL SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 53 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 54 GLOBAL AUTO INJECTOR MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 55 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 56 GLOBAL PEN INJECTOR MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 57 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY
TABLE 58 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS, 2008 - 2015 ($MILLION)
TABLE 59 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 60 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 61 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCTS, (2008 - 2015)
TABLE 62 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 63 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 64 GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 65 GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 66 GLOBAL OCULAR IMPLANTS and OTHERS MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 67 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 68 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 69 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
TABLE 70 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
TABLE 71 REVENUE ANALYSIS, 2008 - 2009
TABLE 72 ELAN TOTAL REVENUES BY DRUG, 2008 - 2010
TABLE 73 ALKERMES TOTAL REVENUES, BY DRUG, 2008 - 2010
TABLE 74 RandD EXPENDITURE, 2008 - 2009
TABLE 75 ELAN’S PIPELINE DRUGS
TABLE 76 BIOVAIL’S PIPELINE DRUGS
TABLE 77 ALKERMES’S PIPELINE DRUGS
TABLE 78 NEKTAR’S PIPELINE DRUGS
TABLE 79 SKYE PHARMA’S PIPELINE DRUGS
TABLE 80 TOP COMPANIES and THEIR STRATEGIES
TABLE 81 BECTON DICKINSON - TOTAL REVENUES, BY SEGMENT ($MILLION)
TABLE 82 BAXTER BIOPHARMA REVENUES, BY SEGMENT
TABLE 83 YPSOMED - TOTAL REVENUES, BY SEGMENT ($MILLION)
TABLE 84 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION, 2008 - 2015
TABLE 85 NORTH AMERICAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
TABLE 86 EUROPEAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
TABLE 87 ASIAN TOP 10 DRUG DELIVERY TECHNOLOGIES
TABLE 88 REST OF THE WORLD TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
TABLE 89 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY, 2009
TABLE 90 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY, 2009
TABLE 91 DIABETES PREVALENCE, BY GEOGRAPHY, 2009
TABLE 92 CANCER PREVALENCE, BY GEOGRAPHY, (2009)
TABLE 93 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY, (2009)
TABLE 94 ANEMIA PREVALENCE, BY GEOGRAPHY, 2009
TABLE 95 HEPATITIS-C PREVALENCE, BY GEOGRAPHY, 2009
TABLE 96 CROHN’S DISEASE PREVALENCE, BY GEOGRAPHY, 2009
TABLE 97 PSORIASIS PREVALENCE, BY GEOGRAPHY, 2009
TABLE 98 TOTAL REVENUES and RandD EXPENDITURE
TABLE 99 TOTAL REVENUES, BY GEOGRAPHY
TABLE 100 TOTAL REVENUES, 2006 - 2010
TABLE 101 SEGMENT SPECIFIC REVENUES ($MILLION)
TABLE 102 TOTAL REVENUES and RandD EXPENDITURE ($MILLION)
TABLE 103 TOTAL REVENUES, BY GEOGRAPHY
TABLE 104 REVENUES, BY SEGMENTS
TABLE 105 TOTAL REVENUES and NET INCOME ($MILLION)
TABLE 106 TOTAL REVENUES, 2007 - 2009
TABLE 107 BAXTER BIOPHARMA - TOTAL REVENUES and RandD EXPENSES ($MILLION)
TABLE 108 BAXTER BIOPHARMA - TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
TABLE 109 BAXTER BIOPHARMA - TOTAL REVENUES, BY SEGMENTS ($MILLION)
TABLE 110 BAXTER BIOPHARMA - TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENTS ($MILLION)
TABLE 111 BECTON DICKINSON - TOTAL REVENUES and RandD EXPENDITURE ($MILLION)
TABLE 112 BECTON DICKINSON - TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
TABLE 113 BECTON DICKINSON - TOTAL REVENUES, BY SEGMENTS ($MILLION)
TABLE 114 BECTON DICKINSON - TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENTS ($MILLION)
TABLE 115 TOTAL REVENUES and RandD EXPENDITURE
TABLE 116 REVENUES, BY SEGMENTS ($MILLION)
TABLE 117 TOTAL REVENUES and RandD EXPENDITURE ($MILLION)
TABLE 118 U.S REVENUES OF BIOVAIL, BY PRODUCTS ($MILLION)
TABLE 119 TOTAL PRODUCT REVENUES OF BIOVAIL PHARMACEUTICALS CANADA
TABLE 120 TOTAL REVENUES and RandD EXPENDITURE
TABLE 121 REVENUES, BY PRODUCTS
TABLE 122 TOTAL REVENUES and RandD EXPENDITURE
TABLE 123 TOTAL REVENUES and RandD EXPENDITURE ($MILLION)
TABLE 124 PRODUCT SALES, BY THERAPEUTIC AREA
TABLE 125 REVENUES and RandD EXPENDITURE
TABLE 126 TOTAL REVENUES and RandD EXPENDITURE
TABLE 127 REVENUES, BY BUSINESS SEGMENTS
TABLE 128 REVENUES, BY PRODUCTS
TABLE 129 REVENUES, BY GEOGRAPHY ($MILLION)
TABLE 130 TOTAL REVENUES and EXPENDITURE
TABLE 131 TOTAL REVENUES and RandD EXPENDITURE
TABLE 132 NEKTAR - TOTAL REVENUES and RandD EXPENSES
TABLE 133 NEKTAR - TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
TABLE 134 QLT - TOTAL REVENUES and RandD EXPENSES ($MILLION)
TABLE 135 QLT - TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
TABLE 136 TOTAL REVENUES and RandD EXPENSES ($MILLION)
TABLE 137 SURMODICS INC. - TOTAL REVENUES and RandD EXPENSES ($MILLION)
TABLE 138 SURMODICS INC. - TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
TABLE 139 SURMODICS INC. - TOTAL REVENUES, BY SEGMENTS ($MILLION)
TABLE 140 TOTAL REVENUES and RandD EXPENDITURE
TABLE 141 YPSOMED - TOTAL REVENUES and RandD EXPENSES ($MILLION)
TABLE 142 YPSOMED - TOTAL REVENUES, BY SEGMENTS ($MILLION)

LIST OF FIGURES

FIGURE 1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES
FIGURE 2 TOP 10 DRUG DELIVERY TECHNOLOGIES - MARKET SHARE
FIGURE 3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY
FIGURE 4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN A DRUG LIFE CYCLE
FIGURE 5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS
FIGURE 6 DRUG DELIVERY MARKET STAKEHOLDERS
FIGURE 7 IMPACT OF MARKET DRIVERS and RESTRAINTS
FIGURE 8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES
FIGURE 9 PATENT ANALYSIS, BY SEGMENTS, (2004 - 2009)
FIGURE 10 PATENT ANALYSIS, BY ASSIGNEE, (2004 - 2009)
FIGURE 11 COMMON REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS
FIGURE 12 EVOLUTION OF CONTROLLED RELEASE TECHNOLOGIES
FIGURE 13 CONTROLLED RELEASE VS IMMEDIATE RELEASE
FIGURE 14 TARGETED THERAPY TYPES
FIGURE 15 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
FIGURE 16 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY
FIGURE 17 EVOLUTION OF INHALER TECHNOLOGY
FIGURE 18 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE
FIGURE 19 COMPETITIVE DEVELOPMENTS, 2007 - JUNE 2010
FIGURE 20 COMPETITIVE DEVELOPMENTS, BY SEGMENTS, 2007 - JUNE 2010
FIGURE 21 REVENUE ANALYSIS, 2008 - 2009
FIGURE 22 CONTROLLED RELEASE, DRUG FORMULATION - MARKET SHARE
FIGURE 23 RandD EXPENDITURE, 2008 - 2009
FIGURE 24 INJECTABLE DRUG DELIVERY DEVICES, MARKET SHARE
FIGURE 25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
FIGURE 26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET - NORTH AMERICA
FIGURE 27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET - EUROPE
FIGURE 28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET - ASIA
FIGURE 29 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET - ROW

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

RNAi Drug Delivery : Technologies and Gobal Markets

RNAi Drug Delivery : Technologies and Gobal Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious ...

Dry Powder Inhalers Market to 2020

Dry Powder Inhalers Market to 2020

  • $ 3 850
  • Industry report
  • June 2014
  • by Greystone Research Associates

Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary ...

Global Analgesic Infusion Pumps Market 2014-2018

Global Analgesic Infusion Pumps Market 2014-2018

  • $ 2 500
  • Industry report
  • June 2014
  • by Infiniti Research Limited

About Analgesic Infusion Pumps Analgesic infusion pumps are devices used for pain management that deliver analgesic drugs into a patient's body. Analgesic drug delivery provides relief from chronic disorders ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.